D:A:D at HIV Drug Therapy Glasgow 2014 2nd-6th November


Poster No: O324. Wednesday Nov 5th at 11.20 AM - 11.35 AM 
“Gender Differences in the Use of Cardiovascular Disease-related Interventions Among HIV-positive persons: D:A:D Study". Presented by Camilla Ingrid Hatleberg. 

Poster No: O322. Wednesday Nov 5th at 10.50 AM -11-05 AM.
 “A clinically useful risk-score for chronic kidney disease (CKD) in HIV infection” . Presented by Amanda Mocroft

Poster No: O315 Wednesday Nov 5th at 09:35 AM - 09:50 AM
“Lack of Association Between Use of Efavirenz and Death from Suicide: D:A:D Study” Presented by Colette Smith


EuroSIDA at HIV Drug Therapy Glasgow 2014 2nd-6th November

Presentations and posters:

Oral session No. O313: Wednesday 5th November 09.05-09.20: Predictive value of Prostate Specific Antigen for prostate cancer: a nested case control study in EuroSIDA. Presented by Leah Shepherd
Oral session No. O234: Tuesday 4th November 14.45-15.00: Regional differences in self-reported HIV care and management in the EuroSIDA study. Presented by Kamilla Laut.

Poster No. P029: The prevalence and predictive value of dipstick protein (DUP) in HIV-positive persons in Europe. Presented by Amanda Mocroft
Poster No. P153: Plasma HIV-1 tropism and risk of short-term clinical progression to AIDS or death. Presented by Maria Casadellà Fontdevila

Poster No. P278: Long term effectiveness of once-daily unboosted atazanavir plus abacavir/lamivudine as a switch strategy in subjects with virological suppression. Presented by Josep M Libre
Poster No. P205: Detection of Resistance Mutations and CD4 Slopes in Individuals Experiencing Sustained Virological Failure. Presented by Anna Schultze


Insight at HIV Drug Therapy Glasgow 2014 2nd-6th November


Oral Presentation O114: Monday 3rd November 09.20-09.35: Factors associated with IL-6 levels during HIV-infection Presented by Alvaro Diniz Borges


HIDES II results at HepHIV2014
The results from the HIDES II surveys on HIV indicator conditions were presented at the recent HepHIV2014 conference (HIV and viral Hepatitis: Challenges for timely testing and care) in Barcelona on October 6th.
Dr Galyna Kutsyna from Ukraine presented the results and her full presentation can be found

MATCH: Poster from IDWeek 2014

Use Of First Positive Cytomegalovirus (CMV) PCR Determination to Differentiate a Viral Blip from Established CMV Infection in Transplant Recipients. A poster from MATCH 


Temporary position - consultant: viral hepatitis technical officer

We are looking for a full-time technical officer for a temporary position starting 1 December 2014 with duration of 2 years.
To find out more please click here


Continued Late Presentation for HIV Care across Europe

See the COHERE presentation from the HepHIV conference here


Regional differences in hepatitis testing, vaccination and treatment in the EuroSIDA study

See the EuroSIDA poster from the HepHIV conference here


Press release: 6th October 2014
HIDES Study identifies new HIV indicator conditions; normalisation of HIV testing
urgently needed to address the hidden epidemic. Follow the link to read more.


Press Release: 1st October 2014

The number of people living with HIV and hepatitis is on the rise in Europe: Follow the link to read more.


Publication: Sept 2014
The latest BMC Infectious Disease supplement “Viral Hepatitis and Drug Use in Europe” is currently live – with contributions from CHIP researchers.

HepHIV2014 Barcelona Conference
HIV and Viral Hepatitis: Challenges of Timely Testing and Care

Crown Plaza Barcelona, Fira Center, 5-7 October 2014
It is still possible to register and be part of this landmark event. Click here for more information.



CHIP is proud to have co-authored the first Global Community Hepatitis Policy Report, published on World Hepatitis Day, 28 July. In this groundbreaking report, published by the World Hepatitis Alliance, civil society organisations from around the world have commented on the information that governments provided last year for the WHO Global Policy Report on the Prevention and Control of Viral Hepatitis.



At the Annual Scientific Meeting, IDWeek -Advancing Science, Improving Care, Taking Place in Philadelphia, PA, from October 8-12 2014, The Following Will Be Presented:

1."Systemic Review and Meta-Analysis of Randomized Controlled Trials (RCTs) Comparing Initial Non-Nucleoside Reverse-Transcriptase Inhibitor (NNRTI)- versus Ritonavir Boosted Protease Inhibitor (PI/r) -based Anti-Retroviral Therapy (ART)"

2."Elevation in Liver Transaminase (ALT-flares) in Transplant (TX) Recipients: Risk factors and Consequences"

3."Clinically Applied Variation in Replication Kinetics During Episodes of Post-Transplant Cytomegalovirus (CMV) Infections"

Poster Presentations:
1."Use of First Positive Cytomegalovirus (CMV) PCR Determination to Differentiate a Viral Blip From Established CMV Infection in Transplant Recipients"



DAD Publication - Available Now
Increased risk of cardiovascular disease (CVD) with age in HIV positive men: a comparison of the D:A:D CVD risk equation and general population CVD risk equations.  K, Petoumenos et al.HIV Medicine 2014. article  

European Commission Cluster Meeting, Athens, 12-13 June 2014

"European Union contribution to a reinforced prevention and improved care in times of HIV epidemic resurgence - How can the European Union support improvement on HIV prevention?

Find out more about the event by following this link


The 6th Nordic Summer HIV meeting

The 6th Summer HIV meeting took place 12 June 2014 in Stockholm. 

Find out more about the meeting by following this link


D:A:D publication in press
Trends over time in underlying causes of death in the D:A:D study 1999-2011. C.J  Smith et al.
Lancet 2014. In press.

CROI 2014
CROI 2014 took place 3 - 6 March 2014 in Boston, Massachusettes. The following was presented at CROI and is available for download: 

Association Between Dideoxynucleoside Analogues (d-drugs) and End-Stage Liver Disease (ESLD) Presented by Lene Ryom on behalf of D:A:D

Predictors of Progression, Stabilisation or Improvement of eGFR After Chronic Renal Impairment Presented by Lene Ryom on behalf of D:A:D

Is there continued evidence for an association between abacavir and myocardial infarction risk? Presented by Caroline Sabin on behalf of D:A:D

Liver-related death among HIV/HCV coinfected individuals, implications for the era of directly acting antivirals Presented by Daniel Grint on behalf of EuroSIDA

PARTNER Data Presented at CROI 2014
Please follow the links below to view the slide presentation and Q&As for the data presented at CROI 2014 from the PARTNER study.


Find out more about the PARTNER study by following this link

CHIP Newsletter to Collaborators
CHIP has recently made substantial changes to its location, image and structure. You can read about these changes and other news in the CHIP Newsletter